Today: 30 June 2026
Snowflake stock slides nearly 9% as Wall Street wobbles, with earnings and Cortex Code update in focus
23 February 2026
2 mins read

Snowflake stock slides nearly 9% as Wall Street wobbles, with earnings and Cortex Code update in focus

NEW YORK, February 23, 2026, 16:54 ET — After-hours

  • Snowflake shares lost 8.6% Monday, holding close to $158 in after-hours trading.
  • Cortex dropped its Code CLI expansion, plus introduced a monthly subscription option beyond its main consumption setup.
  • Another analyst trimmed their target, fueling the pre-earnings churn just before Wednesday’s results.

Snowflake Inc. shares dropped 8.6% to $157.60 on Monday, then hovered around that mark after hours. Investors pulled back from software names ahead of the company’s quarterly results set for later this week. The stock traded between $155.40 and $175.55 during the session.

This isn’t an easy stretch for bullish investors. Snowflake is set to announce earnings Wednesday, with the share price dropping as talk heats up about corporate budgets moving away from standard software and toward rapid-fire AI initiatives.

Snowflake feels the impact of this shift acutely, since its revenue mainly tracks with customer usage, not seat count. Any dip in activity shows up fast in the numbers. Guidance stings more than a simple earnings miss.

Broader market weakness was no help. Monday saw U.S. stocks drop sharply, with software names taking the brunt as traders tried to size up trade policy worries and the expense — plus the shakeup — from new AI tools. “The question about AI is twofold: How much is it going to cost, and who all is going to be disrupted?” said Tom Hainlin, national investment strategist at U.S. Bank Wealth Management. Reuters

Earlier, Snowflake attempted a pivot with its messaging. The company rolled out news that its Cortex Code CLI—a command-line interface tool designed for developers to interact with Snowflake via text prompts—is now extending its reach: it’ll support both dbt and Apache Airflow, not just Snowflake-native workflows. There’s also a new self-service monthly subscription, which doesn’t require Snowflake compute or consumption to use. “Developers don’t operate in a single system, and AI coding assistants shouldn’t either,” EVP of Product Christian Kleinerman said. Barchart.com

BTIG’s Gray Powell kept his buy call on Snowflake but slashed his target price down to $235 from $312, describing the situation as “complicated” going into the report. Powell’s channel checks point to revenue growth sticking near 25%, though he notes some investors are still looking for something closer to 30%. Benzinga

All eyes are on the outlook now. Zacks puts consensus earnings at 27 cents per share, revenue pegged near $1.25 billion. But the quarter itself isn’t really the story—what’s next is what matters. Product revenue draws the sharpest focus, since it reflects customer usage patterns. Remaining performance obligations, the contracted backlog figure, gets close scrutiny from traders, too.

Competition is always lurking. Snowflake faces off with Databricks, plus the major cloud providers—Amazon, Microsoft, Google—all battling for data and AI workloads. If pricing or performance changes, customers have other places to go.

The bear scenario? Simple enough. If guidance turns cautious, usage looks soft, or customers start delaying projects, the stock could stay under pressure. Software valuations are already jittery, and AI headlines keep sparking sharp moves in the market.

Snowflake will report its earnings after the U.S. market shuts on Wednesday, Feb. 25. The company’s conference call is set for 3 p.m. Mountain Time, which lines up with 5 p.m. ET.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Previous Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus
Next Story

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus

Go toTop